Russ, as you mentioned the half yearly will hopefully shed light on their expenditure for the vax programmes so that we have a clearer picture of the extent of the cash burn. IMO I think that the expansion plans are too ambitious and they are juggling too many balls at the moment and I hope that the CFO has his or her eyes on the ball otherwise we could really get into trouble with our cash flow. Don't forget they raised almost $30m during FY2014 and only have $9.6 cash left.
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-78
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.67 |
Change
-0.330(2.20%) |
Mkt cap ! $310.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.50 | $45.94K | 3.131K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 150 | $14.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.67 | 59 | 1 |
View Market Depth
| Last trade - 13.51pm 15/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |